Publications &
Presentations
In our pursuit of scientific advancement we are committed to sharing our acquired knowledge through actively publishing our data in peer-reviewed journals and academic conferences. We aim to provide a deeper understanding through extensive study and analysis on ileal bile acid transporter (IBAT) inhibition, for both the scientific and patient communities.
Research Updates
Featured Presentations & Publications
Impact of pruritus in primary sclerosing cholangitis (PSC): a multinational survey
Kowdley, et al. Poster Presentation, EASL 2022.
Dosing ileal bile acid transporter inhibitors in the fasted state minimizes gastrointestinal adverse effects while maintaining pharmacodynamic effect
Kostrub, et al. Poster Presentation, EASL 2022.
Maralixibat-treated patients with Alagille syndrome (ALGS) demonstrate improved event-free survival in a natural history comparison with patients from the GALA database: application of real-world evidence analytics
Hansen, et al. Presentation, ESPGHAN 2022.
Predictors of 6-year event-free survival in patients with Alagille syndrome treated with maralixibat, an IBAT inhibitor
Sokol, et al. Presentation, ESPGHAN 2022.
Significant improvement in cholestatic pruritus in patients with Alagille syndrome treated with maralixibat, an ileal bile acid transporter inhibitor: Real-world experience
Gonzalez-Peralta, et al. Poster Presentation, ESPGHAN 2022.
Maralixibat improves growth in patients with Alagille syndrome: a 4-year analysis
Kamath, et al. Poster Presentation, ESPGHAN 2022.
Maralixibat treatment response is associated with improved health-related quality of life in patients with bile salt export pump (BSEP) deficiency
Loomes, et al. Presentation, ESPGHAN 2022.
Response to treatment with maralixibat in Alagille syndrome is associated with improved health-related quality of life
Kamath, et al. Poster Presentation, ESPGHAN 2022.
Latest Research Updates
Filter by topic
- SELECT
- Show all
- Alagille syndrome
- Biliary atresia
- Health economics and outcomes research
- IBAT inhibition
- Intrahepatic cholestasis of pregnancy
- LIVMARLI (maralixibat)
- Patient-reported outcomes validation
- Primary biliary cholangitis
- Primary sclerosing cholangitis
- Progressive familial intrahepatic cholestasis
- Volixibat
Until a relevant regulatory agency has approved a Mirum product for a specific disease or population, any scientific presentations regarding such disease or population are not to be considered instruction on the appropriate use of Mirum products or clinical candidates.
